Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20154786 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL11843358 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9098838 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL7364954 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9097633 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9096777 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9099781 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9099300 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL7526762 | 0.98 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL16330120 | 0.94 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906595-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-08-16 | — | — | EP | claimed |
| US-20160220643-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI (FR) | 2016-08-04 | — | — | US | claimed |
| US-9365632-B2 | Exendin-4 derivatives as dual GLP1/glucagon agonists | SANOFI (FR) | 2016-06-14 | — | — | US | claimed |
| US-9181305-B2 | Exendin-4 peptide analogues | SANOFI (FR) | 2015-11-10 | — | — | US | claimed |
| CN-104837864-A | Exendin-4 derivatives as dual GLP1/glucagon agonists | SANOFI SA | 2015-08-12 | — | — | CN | claimed |
| US-20140100156-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI (FR) | 2014-04-10 | — | — | US | claimed |
| CN-114585737-A | Oligonucleotide compositions and methods of use thereof | 波涛生命科学有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-2934567-B9 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP- OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2018-08-22 | — | — | EP | disclosed |
| EP-2934567-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP- OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2018-05-09 | — | — | EP | disclosed |
| EP-2934568-B1 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-10-18 | — | — | EP | disclosed |
| US-9745360-B2 | Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists | SANOFI (FR) | 2017-08-29 | — | — | US | disclosed |
| EP-2906595-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-08-16 | — | — | EP | disclosed |
| EP-2934566-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-06-21 | — | — | EP | disclosed |
| US-9365632-B2 | Exendin-4 derivatives as dual GLP1/glucagon agonists | SANOFI (FR) | 2016-06-14 | — | — | US | disclosed |
| US-20140206608-A1 | Exendin-4 Derivatives | SANOFI (FR) | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206608-A1 | Exendin-4 Derivatives | GLP1R, MC4R, NPY4R | ALDH1A1 3430/4885MAPK1 2793/4885L3MBTL1 2910/4885 |
| US-20160220643-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | GLP1R, GIPR, MC4R | ALDH1A1 3495/4885MAPK1 1523/4885L3MBTL1 2087/4885 |
| US-20140100156-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | GLP1R, GIPR, MC4R | ALDH1A1 3495/4885MAPK1 1523/4885L3MBTL1 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.